A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately

See also
Status	Clinical Trial	Phase
Completed	`NCT02819635` - A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Phase 2/Phase 3
Not yet recruiting	`NCT05960864` - Chinese Spondyloarthritis Inception Cohort (CESPIC)
Not yet recruiting	`NCT05316220` - A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis	Phase 3
Completed	`NCT02345733` - Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis	Phase 4
Terminated	`NCT02217722` - Use of the Ulcerative Colitis Diet for Induction of Remission	N/A
Completed	`NCT02778464` - Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
Completed	`NCT01971814` - Early Serum Infliximab Levels in Severe Ulcerative Colitis.	Phase 1
Completed	`NCT03223012` - Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Active, not recruiting	`NCT03456206` - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed	`NCT04254783` - A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease	Phase 1
Completed	`NCT03398148` - A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2/Phase 3
Withdrawn	`NCT02087878` - A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
Completed	`NCT02065622` - Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis	Phase 3
Completed	`NCT03695185` - A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy	Phase 2
Completed	`NCT02108821` - Fecal Microbiota Transplantation in Pediatric Patients	Phase 1
Terminated	`NCT03758443` - Efficacy & Safety of TD-1473 in Ulcerative Colitis	Phase 2/Phase 3
Completed	`NCT01364896` - Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Terminated	`NCT03920254` - TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study	Phase 2/Phase 3
Recruiting	`NCT01277419` - German Spondyloarthritis Inception Cohort
Recruiting	`NCT05377580` - A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis	Phase 2

NCT number	NCT01848561
Study type	Observational
Source	AbbVie
Contact
Status	Active, not recruiting
Phase
Start date	April 29, 2013
Completion date	June 24, 2030

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms